| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
MRK
Merck & Company
|
Oct 30, 2026 | BUY |
Strong Buy
-3.5% avg upside
44 analysts
|
$170.00
13.67% Upside
|
-4.1% | Β· |
|
GILD
Gilead Sciences
|
Oct 30, 2026 | BUY |
Strong Buy
-27.3% avg upside
66 analysts
|
$184.00
7.88% Upside
|
-0.2% | Β· |
|
LLY
Eli Lilly & Co
|
Oct 30, 2026 | BUY |
Strong Buy
-16.7% avg upside
50 analysts
|
$1650.00
16.46% Upside
|
+1.1% | Β· |
|
BMY
Bristol-Myers Squibb
|
Oct 30, 2026 | HOLD |
Buy
-2.2% avg upside
42 analysts
|
$60.00
4.04% Downside
|
+0.7% | Β· |
|
BIIB
Biogen
|
Oct 29, 2026 | HOLD |
Strong Buy
+6.6% avg upside
53 analysts
|
$250.00
1.33% Downside
|
+0.8% | Β· |
|
REPL
Replimune Group
|
Oct 28, 2026 | BUY |
Strong Buy
+40.9% avg upside
14 analysts
|
$20.00
13.65% Upside
|
+23.4% | Β· |
|
INCY
Incyte
|
Oct 26, 2026 | HOLD |
Buy
-5.9% avg upside
49 analysts
|
$130.00
7.90% Upside
|
+5.6% | Β· |
|
IRON
Disc Medicine
|
Oct 19, 2026 | BUY |
Strong Buy
+23.4% avg upside
21 analysts
|
$120.00
48.49% Upside
|
-3.0% | Β· |
|
AMGN
Amgen
|
Oct 12, 2026 | HOLD |
Buy
-29.9% avg upside
57 analysts
|
$415.00
10.97% Downside
|
+10.7% | Β· |
|
NBIX
Neurocrine
|
Oct 12, 2026 | HOLD |
Strong Buy
+27.3% avg upside
37 analysts
|
$150.00
2.75% Upside
|
+17.4% | Β· |
|
NVO
Novo Nordisk
|
Oct 12, 2026 | HOLD |
Buy
+188.2% avg upside
26 analysts
|
$40.00
0.02% Downside
|
+7.8% | Β· |
|
PFE
Pfizer
|
Oct 12, 2026 | BUY |
Buy
+9.1% avg upside
46 analysts
|
$35.00
14.62% Upside
|
+1.7% | Β· |
|
REGN
Regeneron
|
Oct 12, 2026 | BUY |
Strong Buy
-12.2% avg upside
60 analysts
|
$920.00
0.81% Downside
|
+25.6% | Β· |
|
VRTX
Vertex Pharmaceuticals
|
Oct 12, 2026 | BUY |
Strong Buy
-20.5% avg upside
62 analysts
|
$600.00
7.44% Upside
|
+5.4% | Β· |
|
ABBV
AbbVie
|
Oct 12, 2026 | BUY |
Strong Buy
-14.5% avg upside
47 analysts
|
$300.00
1.74% Upside
|
+1.1% | Β· |
|
AXSM
Axsome Therapeutics
|
Oct 12, 2026 | BUY |
Strong Buy
+63.9% avg upside
30 analysts
|
$310.00
114.73% Upside
|
-18.1% | Β· |
|
SRRK
Scholar Rock Holding
|
Oct 12, 2026 | BUY |
Strong Buy
+48.3% avg upside
23 analysts
|
$84.00
91.28% Upside
|
+7.5% | Β· |
|
BNTX
BioNTech SE
|
Oct 12, 2026 | HOLD |
Strong Buy
+48.9% avg upside
28 analysts
|
$105.00
19.02% Upside
|
-11.5% | Β· |
|
SDGR
Schrodinger
|
Oct 12, 2026 | BUY |
Strong Buy
+7.1% avg upside
16 analysts
|
$30.00
10.49% Upside
|
-1.0% | Β· |
|
PTGX
Protagonist Therapeutics
|
Aug 30, 2026 | BUY |
Strong Buy
-17.0% avg upside
19 analysts
|
$178.00
22.89% Upside
|
-15.6% | Β· |
|
ABCL
AbCellera Biologics
|
Aug 17, 2026 | BUY |
Strong Buy
+33.0% avg upside
18 analysts
|
$15.00
22.31% Upside
|
-1.5% | Β· |
|
MPLT
MapLight Therapeutics, Inc.
|
Aug 13, 2026 | BUY |
Strong Buy
+288.0% avg upside
14 analysts
|
$20.00
163.76% Upside
|
-43.3% | Β· |
|
TSE:APTX
Apotex Health Corp.
|
Aug 12, 2026 | BUY |
Strong Buy
+21.9% avg upside
12 analysts
|
$43.00
28.83% Upside
|
+13.0% | Β· |
|
GPCR
Structure Therapeutics, Inc. Sponsored ADR
|
Aug 06, 2026 | BUY |
Strong Buy
+373.3% avg upside
17 analysts
|
$145.00
563.02% Upside
|
-65.5% | Β· |
|
TSHA
Taysha Gene Therapies
|
Jun 30, 2026 | BUY |
Strong Buy
+241.9% avg upside
22 analysts
|
$14.00
238.99% Upside
|
-41.3% | Β· |
|
ACAD
ACADIA Pharmaceuticals
|
May 11, 2026 | BUY |
Strong Buy
+71.5% avg upside
43 analysts
|
$34.00
65.08% Upside
|
+16.7% | Β· |
|
ARVN
Arvinas Holding Company
|
Sep 30, 2025 | HOLD |
Buy
+257.9% avg upside
28 analysts
|
β | -9.2% | Β· |
|
NGNE
Neurogene
|
Sep 30, 2025 | HOLD |
Buy
+79.4% avg upside
24 analysts
|
β | +60.5% | Β· |
|
CCCC
C4 Therapeutics
|
May 06, 2025 | HOLD |
Strong Buy
+405.9% avg upside
21 analysts
|
β | +107.8% | Β· |
|
DE:MRK
Merck KGaA
|
Oct 23, 2024 | BUY |
Buy
-7.2% avg upside
34 analysts
|
$133.86
11.56% Downside
|
-24.6% | Β· |
|
CADL
Candel Therapeutics
|
Aug 07, 2023 | HOLD |
Strong Buy
+134.0% avg upside
12 analysts
|
β | +369.2% | Β· |
|
NUVB
Nuvation Bio
|
May 09, 2023 | HOLD |
Strong Buy
+177.9% avg upside
18 analysts
|
β | +106.8% | Β· |
|
IMA
ImageneBio
|
Aug 13, 2021 | BUY |
Strong Buy
+336.6% avg upside
13 analysts
|
$27.00
558.51% Upside
|
Β· | Β· |
|
OBX
Obsidian Therapeutics
|
Dec 16, 2020 | BUY |
Strong Buy
+14.6% avg upside
11 analysts
|
$15.00
1.44% Upside
|
Β· | Β· |
|
NL:LKFT
Lakefront Biotherapeutics NV
|
Oct 16, 2020 | HOLD |
Sell
+75.8% avg upside
17 analysts
|
$129.00
345.97% Upside
|
-58.7% | Β· |
|
TLPH
Talphera
|
Aug 13, 2020 | SELL |
Buy
+357.5% avg upside
15 analysts
|
$0.84
18.40% Downside
|
Β· | Β· |
|
MGNX
MacroGenics
|
May 11, 2020 | BUY |
Buy
+638.9% avg upside
25 analysts
|
$30.00
1150.06% Upside
|
+16.1% | Β· |
|
LKFT
Lakefront Biotherapeutics
|
Feb 24, 2020 | HOLD |
Buy
+217.3% avg upside
25 analysts
|
$220.00
581.51% Upside
|
-65.5% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.